
Rothschild Redburn upgraded ICON plc to Buy, raising its price target to $236 from $184, citing the company's undervaluation (P/E 18.1) and anticipating gross bookings to return to year-over-year growth by Q3 2025, viewing recent demand weakness as cyclical rather than structural. This upgrade follows ICON's strong Q2 2025 earnings beat, where EPS of $3.26 surpassed projections, and forecasts a resumption of revenue growth in fiscal year 2026, signaling a positive trajectory despite recent underperformance relative to peers.
ICON plc (ICLR) has received a significant analyst upgrade to Buy from Neutral by Rothschild Redburn, with a price target increase to $236.00 from $184.00. The core rationale is the expectation that recent demand weakness is cyclical, not structural, with a projected return to year-over-year growth in gross bookings by Q3 2025. This positive outlook is substantiated by ICON's recent Q2 2025 performance, where it delivered an earnings beat with an EPS of $3.26, surpassing the $3.19 forecast, alongside stronger-than-expected revenue. The firm's analysis frames ICON's recent underperformance relative to peers like IQVIA and Thermo Fisher's PPD as a temporary issue linked to its exposure to Pfizer and the unwinding of COVID-related projects. While excess cancellation rates may present a near-term headwind through Q3, the forecast anticipates a return to net bookings growth by Q4 2025 and a resumption of overall revenue growth in fiscal year 2026, suggesting a clear recovery path for the contract research organization.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.75
Ticker Sentiment